Nilotinib treatment?associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front?line therapy for chronic myelogenous leukemia

Posted by rob on April 23, 2011 under Uncategorized | Comments are off for this article

AbstractAichberger and colleagues recently described an association between nilotinib therapy for chronic myelogenous leukemia (CML) and adverse vascular events, which occurred in 8 (?33%) of their 24 CML patients treated with nilotinib: severe peripheral artery disease (PAD; n=3), less severe PAD (n=1), sudden death (n=1), myocardial infarction (n=1), spinal infarction (n=1) and subdural hematoma (n=1).1 We were intrigued by these observations because of similar events that occurred in two of our patients receiving nilotinib therapy. A female patient developed severe and unrelenting PAD and coronory artery disease (CAD) after approximately 3 years of treatment with nilotinib and the second patient died suddenly after receiving nilotinib therapy for 3 weeks. None of the two patients had …
More